Zalicus Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain

  Zalicus Advancing Clinical Development of Z944, Its Novel, Oral, T-Type
  Calcium Channel Blocker, for the Treatment of Pain

     Experimental Clinical Study Expected to Initiate Third Quarter 2013

Business Wire

CAMBRIDGE, Mass. -- June 4, 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS) a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced that it is advancing Z944, its novel oral T-type calcium
channel blocker, into further clinical development in the third quarter of
2013. The planned Phase 1b study is a state-of-the-art experimental clinical
model utilizing Laser-Evoked Potentials (LEP) to provide an efficient and
objective assessment of the activity of Z944 in an induced neuropathic pain
state. Results from the LEP study can further inform Zalicus’s development
plans for Z944 in a variety of potential indications.

The LEP clinical model is a type of experimental medicine study designed to
provide both objective and subjective data on a drug’s ability to modulate
pain signaling. In this model electrical voltage fluctuations evoked by laser
thermal stimulation are quantified with vertex-Electroencephalography (EEG) in
addition to a subject-reported pain score. Many currently approved and
emerging pain drugs have been evaluated using the LEP model, providing the
ability to benchmark the efficacy of Z944 against other therapies.

"T-type calcium channels are known to be widely implicated in the frequency
and intensity of pain signals, and we believe Z944 is the most advanced T-type
calcium channel blocker currently in clinical development,” commented Mark
H.N. Corrigan, MD, President and CEO of Zalicus. “The Laser Evoked Potential
experimental model is an efficient way to gather response data in a clinical
setting to further support the potential efficacy of Z944 in pain and inform
future development decisions.”

About Z944 and T-type Calcium Channel Blockers

Z944 is a novel, oral, state-dependent, selective T-type calcium channel
blocker that has demonstrated preclinical efficacy in multiple inflammatory
pain models. T-type calcium channels have been recognized as key targets for
therapeutic intervention in a broad range of cell functions and have been
implicated in pain signaling. Zalicus completed Phase 1 single and multiple
ascending dose clinical studies evaluating the safety and tolerability of Z944
in late 2012 and plans to continue further clinical development during 2013.

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidate Z944, its potential and the plans for its further clinical
preclinical development, the Zalicus selective Ion channel modulation
technology and its other business plans. These forward-looking statements
about future expectations, plans, objectives and prospects of Zalicus and its
product candidates may be identified by words like "believe," "expect," "may,"
"will," "should," "seek," “plan” or “could” and similar expressions and
involve significant risks, uncertainties and assumptions, including risks
related to the development and regulatory approval of Zalicus’ product
candidates, including risks relating to the clinical development of Z944, the
unproven nature of the Zalicus drug discovery technologies, the Company's
ability to obtain additional financing or funding for its research and
development, and those other risks that can be found in the "Risk Factors"
section of Zalicus' annual report on Form 10-K on file with the Securities and
Exchange Commission and the other reports that Zalicus periodically files with
the Securities and Exchange Commission. Actual results may differ materially
from those Zalicus contemplated by these forward-looking statements. These
forward-looking statements reflect management’s current views and Zalicus does
not undertake to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the date of
this release except as required by law.

(c) 2013 Zalicus Inc. All rights reserved.

Contact:

Zalicus Inc.
Justin Renz, CFO, 617-301-7575
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com
 
Press spacebar to pause and continue. Press esc to stop.